Clinical trial
Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors
NCT07399769 is registered in ClinicalTrials.gov with Shenzhen University General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors
- Lead sponsor
- Shenzhen University General Hospital
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- January 1, 2024
- Completion date
- January 30, 2027
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid malignant tumors (with positive expression of msln in tumor tissue)